Table 4.
Significant Associations Between SNPs and Lung Cancer Symptoms (LCSS)
| Outcome | Period | Cytokine | SNP | OR Estimate |
|---|---|---|---|---|
| Pain | 1 | IL-10 | rs1800871 | 0.97–0.99 |
| 2 | IL-10 | rs1800871 | 0.94–0.99 | |
| Fatigue | 1 | IL-1B | rs1143633 | 1.00–1.02 |
| 2 | IL-1B | rs2853550 | 1.01–1.06 | |
| 2 | IL-1RN | rs397211 | 0.97–1.00 | |
| Appetite | 3 | IL-10 | rs3024498 | 1.04–1.46 |
| Dyspnea | 2 | IL-6 | rs2069835 | 0.95–1.00 |
| 3 | IL-1B | rs1143633 | 0.88–0.98 | |
| LC symptoms | 1 | TNF-α | rs1800630 | 1.00–1.02 |
| 1 | IL-1RN | rs397211 | 0.98–1.00 | |
| Hemoptysis | 3 | IL-10 | rs3024498 | 0.27–0.88 |
| 3 | IL-1B | rs1143633 | 1.09–2.43 | |
| QOL | 1 | IL-6 | rs2069843 | 0.96–1.00 |
| 2 | IL-6 | rs2069861 | 1.01–1.05 |
SNPs indicates single nucleotide polymorphisms; LCSS, Lung Cancer Symptom Scale; Period 1, <3 years; Period 2, 3–5 years; Period 3, >5 years; OR, odds ratio; IL, interleukin; LC, lung cancer; TNF-α, tumor necrosis factor-α; QOL, quality of life.